Literature DB >> 2556230

Alterations in arachidonic acid metabolism and chemotactic response in polymorphonuclear leukocytes from patients with rheumatoid arthritis.

D M Smith1, J A Johnson, R A Turner.   

Abstract

This study examines the interrelationship between arachidonic acid (AA) metabolism and chemotactic potential of human peripheral blood neutrophils from both normal donors and patients with rheumatoid arthritis (RA). We demonstrate that there is a significant inverse relationship between the neutrophil's metabolic capability to produce [3H]LTB4 in response to ionophore A23187 stimulation versus the cell's chemotactic potential to optimal concentrations (i.e., 20 nM) of the chemotactic peptide f-Met-Leu-Phe as determined by leading front (r = 0.567, p = 0.009), mean depth (r = 0.458, p = 0.042), and population ratio (r = 0.471, p = 0.036) analyses. Subsequent Percoll density gradient studies revealed several RA neutrophil subpopulations exhibiting significantly enhanced (p less than 0.05) [3H] AA metabolism over corresponding density normal cells. Based on these results, we speculate that RA peripheral blood neutrophils have been "processed" to become less chemotactically-responsive yet more metabolically-active cells, and that the increased ability to produce LTB4 through both increased phospholipase A2 and lipoxygenase activities are part of the increased metabolic capabilities of the cell.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556230

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  2 in total

1.  Changes of fatty acid composition and oxidative metabolism of human neutrophils migrating into an inflammatory exudate.

Authors:  A Carletto; P Bellavite; P Guarini; D Biasi; S Chirumbolo; P Caramaschi; L M Bambara; R Corrocher
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

2.  Evaluation of Tenidap (CP-66,248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis.

Authors:  D M Smith; J A Johnson; R Loeser; R A Turner
Journal:  Agents Actions       Date:  1990-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.